Back to Search

Evaluation of ADG20 for the Prevention of COVID-19

New Orleans, Louisiana, 70118
Detroit, Michigan, 48236
Search open until 02/28/2023

This placebo-controlled study is intended to evaluate ADG20's safety and ability to prevent COVID-19 infection.

Eligibility

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, learn about Clinical

Ages Eligible for Study Min Age: 18 years - Max Age: N/A
Sexes Eligible for Study All
Accepts Healthy Volunteers No

Visit ClinicalTrials.Gov for more information
Support nonprofit organizations through participating in clinical trials at no cost to you
You may also be interested in
Pelham, Alabama and more
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
Cytomegalovirus Infection Read more
Cincinnati, Ohio and more
A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2
SARS-CoV Infection and more Read more
Oklahoma City, Oklahoma and more
Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults
Cytomegalovirus Infection Read more